問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Neurology

Division of Cardiovascular Diseases

更新時間：2025-03-14

莊志明JUANG, JYH-MING JIMMY
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

  • juang.ntuhcvgenetext@gmail.com

  • juang.ntuhcvgenetext@gmail.com

Recruiting Trial

12Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

莊志明

List

41Cases

2019-02-27 - 2023-12-31

Phase III

A PHASE 3 MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826-83) 20 MG OR 80 MG [OR TAFAMIDIS (PF-06291826-00) 61 MG] IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (ATTR-CM)

  • Condition/Disease

    Transthyretin (TTR) Amyloid Cardiomyopathy (ATTR-CM)

  • Test Drug

    Tafamidis (PF-06291826)

Participate Sites
2Sites

Recruiting2Sites

2021-05-03 - 2021-06-11

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2024-05-01 - 2028-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2025-03-07 - 2032-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2011-07-08 - 2013-06-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2012-05-15 - 2014-04-14

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2014-01-31 - 2018-04-30

Phase IV

高血管風險之第2型糖尿病病患使用LINAgliptin 5 mg每天1次的一項多中心、國際性、隨機分配、平行分組、雙盲、安慰劑對照、心血管安全性及腎臟微血管結果試驗。

  • Condition/Disease

    DM

  • Test Drug

    Trajenta® (BI 1356)

Participate Sites
4Sites

Terminated4Sites

2014-12-01 - 2017-07-21

Phase III

A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients with Clinically Evident Cardiovascular Disease and Receiving Statin Background Lipid Lowering Therapy: A Study for Subjects Enrolled in the FOURIER (Study 20110118) Trial

  • Condition/Disease

    Cardiovascular Disease

  • Test Drug

    AMG 145

Participate Sites
8Sites

Terminated8Sites

2021-05-18 - 2023-12-31

Phase II

A Phase 2b, Randomised, Double-Blind, Active-Controlled, Multi-Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients with Heart Failure and Chronic Kidney Disease

  • Condition/Disease

    Heart Failure

  • Test Drug

    AZD9977及Dapagliflozin

Participate Sites
10Sites

Not yet recruiting5Sites

Recruiting5Sites

2012-12-01 - 2016-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Study ended8Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB